S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
Log in
NASDAQ:NTRA

Natera Stock Forecast, Price & News

$120.16
+4.25 (+3.67 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$115.80
Now: $120.16
$122.98
50-Day Range
$84.55
MA: $100.27
$115.91
52-Week Range
$16.87
Now: $120.16
$122.98
Volume1.05 million shs
Average Volume809,498 shs
Market Capitalization$10.26 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.66
Natera, Inc. provides preconception and prenatal genetic testing services. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora products of conception test to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; and Signatera, a circulating tumor DNA technology that analyzes and tracks mutations to an individual's tumor. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners in the United States and internationally. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Natera logo

MarketRank

Overall MarketRank

1.49 out of 5 stars

Medical Sector

382nd out of 1,556 stocks

Medical Laboratories Industry

5th out of 30 stocks

Analyst Opinion: 2.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NTRA
CUSIPN/A
Phone650-249-9090
Employees1,039

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$302.33 million
Book Value$3.59 per share

Profitability

Net Income$-124,830,000.00

Miscellaneous

Market Cap$10.26 billion
Next Earnings Date2/24/2021 (Estimated)
OptionableOptionable
$120.16
+4.25 (+3.67 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NTRA News and Ratings via Email

Sign-up to receive the latest news and ratings for NTRA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Natera (NASDAQ:NTRA) Frequently Asked Questions

How has Natera's stock been impacted by COVID-19 (Coronavirus)?

Natera's stock was trading at $31.02 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NTRA stock has increased by 287.4% and is now trading at $120.16.
View which stocks have been most impacted by COVID-19
.

Is Natera a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Natera in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Natera stock.
View analyst ratings for Natera
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Natera?

Wall Street analysts have given Natera a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Natera wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Natera's next earnings date?

Natera is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021.
View our earnings forecast for Natera
.

How were Natera's earnings last quarter?

Natera, Inc. (NASDAQ:NTRA) released its earnings results on Thursday, November, 5th. The medical research company reported ($0.72) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.67) by $0.05. The medical research company earned $98.14 million during the quarter, compared to the consensus estimate of $87.24 million. Natera had a negative net margin of 52.11% and a negative return on equity of 53.39%. The firm's revenue for the quarter was up 26.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.33) earnings per share.
View Natera's earnings history
.

What guidance has Natera issued on next quarter's earnings?

Natera updated its FY 2020 After-Hours earnings guidance on Thursday, November, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $380-390 million, compared to the consensus revenue estimate of $359.49 million.

What price target have analysts set for NTRA?

10 Wall Street analysts have issued 1-year target prices for Natera's shares. Their forecasts range from $36.00 to $127.00. On average, they anticipate Natera's share price to reach $88.30 in the next year. This suggests that the stock has a possible downside of 26.5%.
View analysts' price targets for Natera
or view Wall Street analyst' top-rated stocks.

Who are some of Natera's key competitors?

What other stocks do shareholders of Natera own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Natera investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil Co. (ATH.TO) (ATH), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Transocean (RIG) and Allergan (AGN).

Who are Natera's key executives?

Natera's management team includes the following people:
  • Dr. Matthew Rabinowitz, Co-Founder & Exec. Chairman (Age 48, Pay $497.18k)
  • Mr. Steve Chapman, CEO, Pres & Director (Age 42, Pay $680.92k)
  • Mr. Jonathan Sheena, Co-Founder, Chief Technology Officer & Director (Age 48, Pay $297.13k)
  • Mr. Michael Brophy, Chief Financial Officer (Age 41, Pay $521.62k)
  • Mr. Robert A. Schueren, Chief Operating Officer (Age 59, Pay $626.18k)
  • Mr. Eric A. Evans, Chief Scientific Officer
  • Mr. Daniel Rabinowitz L.L.M., LL.M., Sec. & Gen. Counsel
  • Mr. Phil Grinnell, VP of Sales
  • Dr. Ramesh Hariharan, VP of Marketing & Medical Education
  • Paul Greenland, VP of Corp. Marketing

When did Natera IPO?

(NTRA) raised $101 million in an IPO on Thursday, July 2nd 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

What is Natera's stock symbol?

Natera trades on the NASDAQ under the ticker symbol "NTRA."

How do I buy shares of Natera?

Shares of NTRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Natera's stock price today?

One share of NTRA stock can currently be purchased for approximately $120.16.

How big of a company is Natera?

Natera has a market capitalization of $10.26 billion and generates $302.33 million in revenue each year. The medical research company earns $-124,830,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Natera employs 1,039 workers across the globe.

What is Natera's official website?

The official website for Natera is www.natera.com.

How can I contact Natera?

Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The medical research company can be reached via phone at 650-249-9090 or via email at [email protected]

This page was last updated on 1/17/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.